Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.
about
NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.MHC class II tetramersProfile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.Northern peatland initiation lagged abrupt increases in deglacial atmospheric CH4.MHC class II tetramers made from isolated recombinant α and β chains refolded with affinity-tagged peptides.Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.CD4(+) T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs.MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS.HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patientsAnalysis, Isolation, and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-Peptide Complexes.IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.Basic principles of tumor-associated regulatory T cell biology.Viral-specific adoptive immunotherapy after allo-SCT: the role of multimer-based selection strategies.MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cellsImpact of T cell selection methods in the success of clinical adoptive immunotherapy.AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
P2860
Q33987977-40458D1E-C15E-4A55-A33B-FCDB063F8501Q34258556-453B0B84-76C8-4AE0-AACD-07E0777940C0Q34338725-9B444060-047D-4087-91AA-B6C63739F31FQ34461203-20CB5B9D-2EEA-407B-B009-512926990F22Q34721054-5AD89E1D-0ED0-42DA-9F42-4868F4442096Q34984511-D7F7F6F7-398A-44EE-B31B-1750CC40F9EBQ36249440-F7CBFCFD-FC38-4C3F-915E-1361D176C245Q36256035-308AC115-3F46-46DF-AD2A-2A8FCD2622D2Q36579158-7A0E371D-5745-466F-8DF5-DA52E443D9E2Q37012650-076C2B1E-6A5D-4404-B8C3-850B7A26340EQ37028039-DBA5EE5A-405A-478A-A4E8-44FC2AC8995BQ37054621-B00BD4F1-D160-4812-9092-4AF0AAAEC187Q37078985-257D979D-9654-4AFA-B2CF-2604500CBC98Q38045603-97F7015E-A11B-4BE4-85D4-824FB4D0031EQ38074019-FF7B0249-EAB1-44AE-9B95-3BA6EB93EBAEQ40987678-9B675C6B-205F-4D3C-A6E5-20B07BF7DDA9Q42265908-B8E98FBE-8A13-4DE5-87DC-35F62D58A585Q44644226-CE871100-50D9-4302-AD1C-A742F5240BCB
P2860
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Monitoring of NY-ESO-1 specifi ...... II/His-tag-peptide tetramers.
@ast
Monitoring of NY-ESO-1 specifi ...... II/His-tag-peptide tetramers.
@en
type
label
Monitoring of NY-ESO-1 specifi ...... II/His-tag-peptide tetramers.
@ast
Monitoring of NY-ESO-1 specifi ...... II/His-tag-peptide tetramers.
@en
prefLabel
Monitoring of NY-ESO-1 specifi ...... II/His-tag-peptide tetramers.
@ast
Monitoring of NY-ESO-1 specifi ...... II/His-tag-peptide tetramers.
@en
P2093
P2860
P356
P1476
Monitoring of NY-ESO-1 specifi ...... s II/His-tag-peptide tetramers
@en
P2093
Danijel Dojcinovic
Danila Valmori
Immanuel Luescher
Isabelle Raimbaud
Julien Schmidt
Pascale Pignon
P2860
P304
P356
10.1073/PNAS.1001322107
P407
P50
P577
2010-04-05T00:00:00Z